Alaunos Therapeutics (TCRT) Competitors $2.26 -0.05 (-2.16%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. LSTA, MTEX, ABP, LSB, SYBX, IXHL, EDSA, THAR, AIMD, and TLPHShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Lisata Therapeutics (LSTA), Mannatech (MTEX), Abpro (ABP), LakeShore Biopharma (LSB), Synlogic (SYBX), Incannex Healthcare (IXHL), Edesa Biotech (EDSA), Tharimmune (THAR), Ainos (AIMD), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Its Competitors Lisata Therapeutics Mannatech Abpro LakeShore Biopharma Synlogic Incannex Healthcare Edesa Biotech Tharimmune Ainos Talphera Alaunos Therapeutics (NASDAQ:TCRT) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership. Is TCRT or LSTA more profitable? Lisata Therapeutics' return on equity of -69.68% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -168.02% -121.37% Lisata Therapeutics N/A -69.68%-59.44% Do analysts rate TCRT or LSTA? Lisata Therapeutics has a consensus target price of $23.50, indicating a potential upside of 949.11%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in TCRT or LSTA? 27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media refer more to TCRT or LSTA? In the previous week, Alaunos Therapeutics had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 3 mentions for Alaunos Therapeutics and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.45 beat Alaunos Therapeutics' score of 0.63 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Alaunos Therapeutics Positive Lisata Therapeutics Positive Which has more risk and volatility, TCRT or LSTA? Alaunos Therapeutics has a beta of -0.82, indicating that its share price is 182% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Which has stronger earnings and valuation, TCRT or LSTA? Alaunos Therapeutics has higher earnings, but lower revenue than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos Therapeutics$10K499.46-$4.68M-$2.46-0.92Lisata Therapeutics$1M19.62-$19.99M-$2.23-1.00 SummaryLisata Therapeutics beats Alaunos Therapeutics on 9 of the 15 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.00M$2.54B$5.76B$10.27BDividend YieldN/A57.24%5.73%4.60%P/E Ratio-0.9223.5275.4426.24Price / Sales499.46545.32457.8390.99Price / CashN/A27.5625.8129.91Price / Book1.755.4213.236.30Net Income-$4.68M$32.95M$3.29B$270.76M7 Day Performance3.20%1.12%0.93%3.03%1 Month Performance0.44%5.26%5.14%6.38%1 Year Performance-3.00%-1.48%74.06%26.35% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics0.3309 of 5 stars$2.26-2.2%N/A-0.9%$5.00M$10K-0.9240LSTALisata Therapeutics3.2413 of 5 stars$2.20+0.9%$23.50+968.2%-24.7%$19.09M$1M-0.9930Positive NewsShort Interest ↓Gap DownMTEXMannatech0.9853 of 5 stars$9.12-2.7%N/A+7.2%$17.81M$117.87M-4.47250Short Interest ↓ABPAbpro3.9497 of 5 stars$0.17-21.5%$4.00+2,241.9%N/A$17.44M$180K0.0015Positive NewsHigh Trading VolumeLSBLakeShore Biopharma1.2273 of 5 stars$0.84+0.2%N/A-86.1%$17.34M$85.67M0.00773Short Interest ↓Gap DownSYBXSynlogic1.6433 of 5 stars$1.48+0.7%N/A+13.6%$17.20M$10K-18.5080Positive NewsShort Interest ↓IXHLIncannex Healthcare0.1489 of 5 stars$0.55-6.3%N/A-66.4%$17.13M$10K-0.453Short Interest ↑Gap UpEDSAEdesa Biotech1.4488 of 5 stars$2.43+0.4%$5.00+105.8%-43.9%$17.03MN/A-1.8420THARTharimmune2.4518 of 5 stars$2.79-5.7%$17.00+509.3%+5.7%$16.85MN/A-0.462Gap UpAIMDAinos1.0707 of 5 stars$3.38-6.4%N/A+34.4%$16.82M$20K-0.6840TLPHTalphera2.0096 of 5 stars$0.85+4.2%$5.00+486.2%+4.4%$16.81M$650K-2.1319Gap Up Related Companies and Tools Related Companies Lisata Therapeutics Alternatives Mannatech Alternatives Abpro Alternatives LakeShore Biopharma Alternatives Synlogic Alternatives Incannex Healthcare Alternatives Edesa Biotech Alternatives Tharimmune Alternatives Ainos Alternatives Talphera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRT Stock Alerts